- Chemical Name:2,2-dichloro-2-phenylacetamide
- CAS No.:7598-13-2
- Molecular Formula:C8H7 Cl2 N O
- Molecular Weight:204.056
- Hs Code.:
Synonyms:NSC401665
Synonyms:NSC401665
There total 4 articles about 2,2-dichloro-2-phenylacetamide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:
Reference yield:
Reference yield:
Reference yield:
The study focuses on the synthesis of novel σ-receptor ligands using methyl α-D-mannopyranoside as the starting material. This is the first time a monosaccharide has been utilized for the creation of such ligands, which have potential applications as antipsychotics, antidepressants, anticocaine agents, and antitumor agents. The researchers employed various chemicals in the synthesis process, including nitrile 7, which was transformed into hept-3-ulopyranoside dimethyl ketals 14 and 15 through two different synthetic routes. Amino substituents were introduced into position 3 after selective hydrolysis of the ketone dimethyl acetal. The study identified that a dichlorophenylacetamide moiety in position 7 and equatorially arranged amino substituents in position 3 were crucial for high σ1-receptor affinity and selectivity. The synthesized compounds were then tested for their affinity and selectivity towards σ1 and σ2 receptors, as well as their interaction with other receptor systems such as the phencyclidine binding site of the NMDA receptor, δ-opioid, and μ-opioid receptors. The most active compound in the series, an anomeric mixture of dimethylamines 26a/b, showed the highest σ1-receptor affinity with a Ki value of 21 nM. The study demonstrated the potential of using monosaccharides as building blocks for the development of new drugs with high σ1-receptor affinity and selectivity.